See more : Grab Holdings Limited (GRAB) Income Statement Analysis – Financial Results
Complete financial analysis of bioAffinity Technologies, Inc. (BIAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of bioAffinity Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Shenzhen Bsc Technology Co.,Ltd. (300951.SZ) Income Statement Analysis – Financial Results
- Grosvenor Resource Corporation (GVR.V) Income Statement Analysis – Financial Results
- T&S inc. (4055.T) Income Statement Analysis – Financial Results
- Kingswood Holdings Limited (KWG.L) Income Statement Analysis – Financial Results
- Doha Bank Q.P.S.C. (DHBK.QA) Income Statement Analysis – Financial Results
bioAffinity Technologies, Inc. (BIAF)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.bioaffinitytech.com
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.53M | 4.80K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 467.00 | 4.82K | 22.24K | 40.28K |
| Gross Profit | 791.62K | 4.34K | -4.82K | -22.24K | -40.28K |
| Gross Profit Ratio | 31.26% | 90.28% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.72M | 1.29M | 1.33M | 1.61M | 1.85M |
| General & Administrative | 0.00 | 2.73M | 880.77K | 994.34K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.79M | 2.73M | 880.77K | 994.34K | 1.20M |
| Other Expenses | 249.59K | -1.87M | 724.93K | -4.28M | 0.00 |
| Operating Expenses | 8.76M | 4.02M | 2.21M | 2.60M | 3.05M |
| Cost & Expenses | 10.51M | 4.02M | 2.21M | 2.60M | 3.09M |
| Interest Income | 122.13K | 46.71K | 424.00 | 1.07K | 2.78K |
| Interest Expense | 37.13K | 2.53M | 1.00M | 382.17K | 214.83K |
| Depreciation & Amortization | 249.59K | 10.18K | 4.82K | 22.24K | 40.28K |
| EBITDA | -7.63M | -5.61M | -2.20M | -6.86M | -3.05M |
| EBITDA Ratio | -301.26% | -121,196.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.97M | -4.01M | -2.21M | -2.60M | -3.09M |
| Operating Income Ratio | -314.84% | -83,511.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 57.21K | -4.14M | -4.12M | -4.66M | -212.06K |
| Income Before Tax | -7.92M | -8.15M | -6.32M | -7.27M | -3.30M |
| Income Before Tax Ratio | -312.58% | -169,720.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 20.99K | 2.46K | 1.95K | 2.75K | 3.20K |
| Net Income | -7.94M | -8.15M | -6.33M | -7.27M | -3.31M |
| Net Income Ratio | -313.41% | -169,771.25% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| EPS Diluted | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| Weighted Avg Shares Out | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
| Weighted Avg Shares Out (Dil) | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development.
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests...
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement.
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests...
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at risk for lung cancer.
WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
JERSEY CITY, N.J. , Aug. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that in connection with the BioAffinity Technologies (NASDAQ: BIAF) warrant exercise agreements dated August 2, 2024,...
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of registered direct offering, private placement and warrant inducement for gross proceeds of $1.75 million.
WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
JERSEY CITY, N.J. , Aug. 2, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF) (the "Company") has entered into warrant exercise agreements with three...
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July...
Source: https://incomestatements.info
Category: Stock Reports